Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.

BACKGROUND Adapalene is a new chemical entity that exhibits tretinoin-like activities in the terminal differentiation process. OBJECTIVE We evaluated a dose range effect of two concentrations of adapalene gel as acne treatment and compared adapalene 0.1% gel with tretinoin 0.025% gel in the treatment of acne patients in two large multicenter studies. METHODS Multicenter, investigator-masked, parallel group studies including 89 acne patients in the dose range study and 591 patients in the concurrent controlled studies were conducted. RESULTS Adapalene gel 0.1% was significantly more effective in treating acne lesions than 0.03% adapalene gel. Adapalene gel 0.1% was significantly more effective than 0.025% or tretinoin gel in one study and of the same effectiveness in the other study. Adapalene gel was always better tolerated than tretinoin gel. CONCLUSION Adapalene 0.1% gel is a safe and effective treatment of acne vulgaris.

[1]  B. Bernard.  Adapalene, a new chemical entity with retinoid activity. , 1993, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[2]  D. Elbaum.  Comparison of the stability of topical isotretinoin and topical tretinoin and their efficacy in acne. , 1988, Journal of American Academy of Dermatology.

[3]  C. Redfern.  Molecular markers of retinoid activity in skin. , 1994, Journal of Investigative Dermatology.

[4]  W. Cunliffe,et al.  The assessment of acne vulgaris—the Leeds technique , 1984, The British journal of dermatology.

[5]  J. Czernielewski,et al.  A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. , 1996, Journal of the American Academy of Dermatology.

[6]  J. Czernielewski,et al.  Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris , 1991, The British journal of dermatology.

[7]  J. Voorhees,et al.  Expression, purification, and binding properties of human cellular retinoic acid-binding protein type I and type II. , 1993, Archives of biochemistry and biophysics.

[8]  James T. Elder,et al.  Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. , 1993, The Journal of investigative dermatology.

[9]  B. Shroot,et al.  Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP). , 1992, The Journal of investigative dermatology.